



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Arlene H. Sharpe et al.

Serial No.: 08/702,525

Filed: February 7, 1997

For: NOVEL FORMS OF T CELL  
COSTIMULATORY MOLECULES AND USES  
THEREFOR

Attorney Docket No.: BWI-120CPUS

Group Art Unit: 1644

Examiner: P. Gambel

RESPONSE UNDER 37 CFR 1.116  
- EXPEDITED PROCEDURE  
EXAMINING GROUP 1644

17/c  
D.G.J.  
6/15/99  
(NE)

Assistant Commissioner for Patents  
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

June 8, 1999  
Date of Signature and of Mail Deposit

By:

DeAnn F. Smith  
DeAnn F. Smith  
Reg. No. 36,683  
Attorney for Applicants

**AMENDMENT AND RESPONSE AFTER FINAL**

Dear Sir:

This Amendment and Response is being filed in response to the final Office Action dated December 8, 1998 (Paper No. 14). A separate request for an appropriate extension of time and Notice of Appeal is being filed concurrently herewith. In response to the Action, please amend the application as follows:

In the claims:

Please amend the claims as follows:

C  
9. (Twice Amended) An isolated nucleic acid molecule encoding a B7-1 or B7-2 protein which binds CD28 or CTLA4 and which is an alternative splice form of a transcript of a B7-1 or B7-2 T cell costimulatory molecule gene having at least one first exon encoding a B7-1 or B7-2 first cytoplasmic domain comprising a nucleotide sequence selected from